SLC18A2 Antibody, FITC conjugated

Code CSB-PA021427LC01HU
Size US$299 How to order?
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Full Product Name Rabbit anti-Homo sapiens (Human) SLC18A2 Polyclonal antibody
Uniprot No. Q05940
Target Names SLC18A2
Alternative Names 1110037L13Rik antibody; 9330105E13 antibody; MGC120477 antibody; MGC120478 antibody; MGC26538 antibody; MGC90556 antibody; MNAT antibody; Monoamine neurotransmitter transporter antibody; Monoamine transporter antibody; OTTHUMP00000020576 antibody; SLC18A2 antibody; Solute carrier family 18 (vesicular monoamine) member 2 antibody; Solute carrier family 18 member 2 antibody; SVAT antibody; SVMT antibody; Synaptic vesicle amine transporter brain antibody; Synaptic vesicle monoamine transporter brain antibody; Synaptic vesicular amine transporter antibody; VAT 2 antibody; VAT2 antibody; Vesicle monoamine transporter type 2 antibody; Vesicle monoamine/H+ antiporter antibody; Vesicular amine transporter 2 antibody; Vesicular monoamine transporter 2 antibody; VMAT 2 antibody; VMAT2 antibody; VMAT2_HUMAN antibody
Raised in Rabbit
Species Reactivity Human
Immunogen Recombinant Human Synaptic vesicular amine transporter protein (463-514AA)
Immunogen Species Homo sapiens (Human)
Conjugate FITC
Clonality Polyclonal
Isotype IgG
Purification Method >95%, Protein G purified
Concentration It differs from different batches. Please contact us to confirm it.
Buffer Preservative: 0.03% Proclin 300
Constituents: 50% Glycerol, 0.01M PBS, pH 7.4
Form Liquid
Troubleshooting and FAQs Antibody FAQs
Storage Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
Lead Time Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Target Background

Involved in the ATP-dependent vesicular transport of biogenic amine neurotransmitters. Pumps cytosolic monoamines including dopamine, norepinephrine, serotonin, and histamine into synaptic vesicles. Requisite for vesicular amine storage prior to secretion via exocytosis.
Gene References into Functions
  1. single nucleotide polymorphisms (rs363223, rs363226, rs363251, and rs363341interact with assessed cognitive impairment after severe traumatic brain injury PMID: 26828714
  2. This study showed that in Chinese patient population, "GG" of rs363371 in VMAT2 may reduce the risk for ALS. PMID: 28477711
  3. We found a novel association between two genetic variants in SLC18A2 and FSH levels in PCOS patients. These findings might indicate a novel regulatory mechanism in follicular development and maturation in PCOS. PMID: 27354380
  4. The SLC18A2 gene is hypermethylated and downregulated in prostate cancer (PC). SLC18A2 hypermethylation has promising diagnostic biomarker potential for PC. PMID: 26905753
  5. Study found that 2 promoter regions of Vesicular monoamine transporter 2 (hVMAT2) are associated with Parkinson's disease. Study shows that low-activity haplotypes may confer more vulnerability in the presence of a neurotoxin and that hVMAT2 activity could be inhibited by DNA methylation in human dopaminergic neurons. PMID: 27137201
  6. No statistically significant differences were found between cases and controls for the allele frequencies in five genes: TH, SLC18A2, DRD1, DRD3 and COMT. Conversely, some alleles of the 12 sNPs from the DRD2 locus and the 5 from the MAOA locus showed significant associations with excessive alcohol consumption. PMID: 26447226
  7. describe a second case of infantile-onset movement disorder caused by a different mutation in SLC18A2 compared to PMID:23363473, and partial improvement of symptoms upon treatment with pramipexole; supports identification of causal mutation in index case. PMID: 26497564
  8. Two SNPs (rs10082463 & rs363285) of SLC18A2 were nominally associated with cognition. PMID: 23932573
  9. The finding of this study provide support for a role of VMAT2 in tardive dyskinesia and add to evidence that VMAT2 may be a potential therapeutic target in the treatment of TD. PMID: 24018103
  10. VMAT2 genetic variants contribute to the phenotypes of alcohol dependence. PMID: 23504072
  11. Genetic variation in VMAT2 may be linked to alterations in cognitive functioning underlying psychotic disorder, possibly through altered transport of monoamines into synaptic vesicles. PMID: 22532702
  12. In an Italian cohort, variability in VMAT2 promoter region appears to confer a reduced risk of developing Parkinson's disease. PMID: 23369548
  13. VMAT2 expression dynamically decreased in the neocortex of temporal lobe epilepsy patients when compared with the control subjects. PMID: 23504951
  14. Data suggest that pancreatic islets of humans and pigs contain VMAT2 in similar patterns (in beta cells, mast cells, and sympathetic neurons); therefore, the pig (unlike rodents) is potential model for imaging pancreas using radioligands for VMAT2. PMID: 23404442
  15. Chromogranin A and vesicular monoamine transporter 2 are localized in protein bodies of human locus coeruleus neurons. PMID: 23573890
  16. These results may indicate that VMAT2 expressed in noradrenergic neurons has crucial roles in survival during the first several weeks after birth, and VMAT2 functions in other monoaminergic systems could be required for further extended survival. PMID: 23410751
  17. Study evaluated VMAT2 specificity for beta cells in sub-regions of the human pancreas using antibodies targeting VMAT2, insulin and PP by double-label immunofluorescence. PMID: 23221614
  18. homology model of VMAT2 shows that molecular hinge points mediate alternating access PMID: 23530208
  19. describe a disease encompassing infantile-onset movement disorder and evidence supporting its causation by a mutation in SLC18A2 (which encodes vesicular monoamine transporter 2 [VMAT2]) PMID: 23363473
  20. These results support our hypothesis that VMAT-2 and DT-diaphorase are an important defense system against aminochrome formed during dopamine oxidation. PMID: 22483869
  21. These results indicate that wild-type DJ-1, but not Parkinson's disease-derived mutant DJ-1, stimulates VMAT2 activity and that C106 is necessary for the stimulating activity of DJ-1 toward VMAT2. PMID: 22554508
  22. In an aversive ultrasound-induced defense paradigm, VMAT2(sert-cre) transgenic mice displayed a major increase in escape-like behaviors. PMID: 21814181
  23. This preliminary finding indicates a possible structural change in platelet VMAT2 in children with major depressive disorder. PMID: 21484276
  24. there is no difference in levels of vesicular monoamine transporter 2 between children with disruptive behavior disorders and healthy volunteers PMID: 21851191
  25. Distribution of vesicular monoamine transporter 2 protein in human brain: implications for brain imaging studies. PMID: 21522164
  26. A significant reduction of platelet VMAT2 mRNA levels was demonstrated in Parkinson Disease patients versus healthy controls PMID: 20665056
  27. Six electroconvulsive therapy sessions are not sufficient for modulation in pVMAT2 expression. Long-term studies are needed to clarify the relationship between full remission and possible alterations in platelet/brain VMAT2 characteristics. PMID: 20544232
  28. greater diversity of transcriptional regulations is the driving force for the haplotype selection in SLC18A2 PMID: 20181938
  29. Voxel-based analysis demonstrated VMAT2 reductions in the striatum and mid brain of Parkinson disease patients. PMID: 20080893
  30. Assessment of the VMAT2 thrombin cleavage site reveals that the Cys-126 in loop 1/2 and Cys-333 in loop 7/8 form a disulfide bond which contributes to efficient monoamine transport. PMID: 12009896
  31. Striatal VMAT2 expression was reduced significantly in dementia with Lewy bodies with or without Alzheimer's disease, but was preserved in Alzheimer's disease striatum, permitting postmortem distinction of the two pathologies. PMID: 12112084
  32. striatal expression of VMAT2 (as estimated by [(11)C]DTBZ binding) is not coregulated with dopamine synthesis. This is in keeping with a role for VMAT2 in other cellular processes in addition to its importance for the quantal release of monoamines. PMID: 12710012
  33. vesicular monoamine transporter (VMAT2) mRNA was not detected in the central part of the placenta but was present in the spiral arteries of placenta bed biopsies PMID: 15135235
  34. two single nucleotide polymorphisms were identified that have no detectable effect on most aspects of VMAT2 function, but one may increase sensitivity to the inhibitor tetrabenazine PMID: 15475732
  35. SLC18A2 promoter haplotypes defined here create a foundation for transcriptional characterization of individuality and for association study on monoamine-related human diseases PMID: 15829504
  36. VMAT2 pharmacodynamic characteristics in a population of medicated schizophrenia patients comparing smokers and nonsmokers. PMID: 16139173
  37. Gain-of-function haplotypes in the SLC18A2 promoter are protective for Parkinson disease in women. PMID: 16339215
  38. Low expression of VMAT2 in the substantia nigra of Parkinson's disease , the involvement of VMAT2 in Lewy body of the substantia nigra suggests the association of this protein in the neurodegeneration of nigral neurons in Parkinson's disease. PMID: 16386370
  39. VMAT 2 antibodies seem more useful for histopathological diagnosis of enterochromaffin-like cell neoplasms than the antibodies to the other CgA regions. PMID: 16408221
  40. This review summarizes the possible role of VMAT2 as a therapeutic target and discusses the structure-activity relationships and binding relevance of the VMAT2 ligands reported in the literature. PMID: 17233532
  41. lower platelet VMAT2 density occurred in the brain and may serve as an adaptive mechanism geared to decrease dopamine storage PMID: 17344033
  42. These results strongly suggest that SVMT gene or certain regions of it may constitute a genetic substrate of susceptibility for both schizophrenia and bipolar disorder. PMID: 17427184
  43. data suggest that elements of the 20 S proteasome interact with the VMAT2 promoter to enhance G-protein-coupled receptor-mediated transcription PMID: 17442673
  44. Mishandling of dopamine via reduced VMAT2 transgenic expression causes dopamine-mediated toxicity and neurodegeneration in the mouse nigrostriatal dopamine system, replicating key aspects of Parkinson's disease. PMID: 17652604
  45. review of the regulation of VMAT2 and the state of the understanding of what measurements of VMAT2 density mean in the context of diabetes PMID: 17665159
  46. These data suggest that up-regulated alpha-synuclein expression inhibits the activity of vesicular monoamine transporter-2. PMID: 17985233
  47. Variation in SLC18A2 is implicated as risk factor for schizophrenia. PMID: 18045777
  48. variation in the VMAT2 gene plays a role in one's openness to spiritual experiences PMID: 18316816
  49. Rotenone redistributes VMAT2 via nitration in dopaminergic SH-SY5Y cells. PMID: 18599602
  50. Most beta cells expressed VMAT2. VMAT2 expression was not changed by the presence of diabetes. PMID: 18791800

Show More

Hide All

Subcellular Location Cytoplasmic vesicle membrane; Multi-pass membrane protein.
Protein Families Major facilitator superfamily, Vesicular transporter family
Database Links

HGNC: 10935

OMIM: 193001

KEGG: hsa:6571

STRING: 9606.ENSP00000298472

UniGene: Hs.596992

Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
7505 Fannin St. Ste 610-312, Houston, TX 77054, USA
Join Us with

Subscribe newsletter

Leave a message

© 2007-2022 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1